New immune therapy targets Hard-to-Treat multiple myeloma
NCT ID NCT05411497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T cells) that are specially trained to recognize and attack cancer cells carrying a protein called MUC1. The main goals are to check safety and find the best dose in a small group of 5 adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer transplant study tests safer GVHD prevention
- New hope for hard-to-treat myeloma: three-drug combo enters phase 2 trial
- Stem cell transplant study seeks best way to prevent immune attack
- New immune cell therapy takes on Hard-to-Treat myeloma
- New combo tackles resistant myeloma in early trial
- New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients